Skip to main content
Cloudbreak Pharma Inc. logo

Cloudbreak Pharma Inc. — Investor Relations & Filings

Ticker · 2592 HKEX Manufacturing
Open in API
Filings indexed 71 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2592

About Cloudbreak Pharma Inc.

https://cloudbreakpharma.com/

Cloudbreak Pharma Inc. is an innovative, clinical-stage ophthalmology biotechnology company dedicated to the research and development of novel and differentiated treatments for chronic eye diseases. The company focuses on improving vision quality globally by developing therapies for both anterior and posterior segment ophthalmic conditions. Its robust pipeline includes products targeting pterygium, pinguecula, meibomian gland dysfunction, glaucoma filtration surgery, age-related macular degeneration, and diabetic retinopathy. Cloudbreak utilizes advanced platforms, including a potent multi-kinase inhibitor formulated as a topical eye drop for anterior segment diseases and a unique Antibody-Drug Synergism Platform for posterior segment diseases.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-04 English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE IN RELATION TO INVESTIGATIONAL NEW DRUG APPLICATION FOR CBT-199 COMPLETED SAFETY REVIEW BY FOOD AND DRUG ADMINISTRATION
Regulatory Filings
2026-04-30 English
UPDATE ANNOUNCEMENT
Regulatory Filings Classification · 72% confidence The document is a standalone update announcement filed with the Stock Exchange of Hong Kong regarding the redemption of a fund previously disclosed in an earlier announcement. There is no detailed financial report or earnings data, nor is it an Annual/Interim report, management change, dividend, or voting result. It is not a proxy statement or AGM material, but rather a regulatory announcement updating investors on a specific corporate transaction (fund redemption) that does not fit into more specific categories. Therefore, it falls under the general “Regulatory Filings” category (RNS).
2026-04-22 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 85% confidence The document is an official Hong Kong Stock Exchange ‘Next Day Disclosure Return’ (Form FF305) reporting changes in issued shares (new share allotments under an equity incentive scheme) and disclosures on treasury shares/repurchases. It is not an earnings release, AGM material, management commentary, or a high-level report announcement. The primary purpose is to announce and detail a capital change (issuance of new shares). This matches the “Share Issue/Capital Change” category (Code: SHA).
2026-04-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 85% confidence The document is an Exchange (HKEX) form FF301 – a mandatory monthly return detailing movements in authorised share capital, issued shares, treasury shares and public float confirmation under Chapter 19B of the Listing Rules. It is a routine regulatory submission, not an AGM/annual report, earnings release or capital raise announcement. It does not itself announce a dividend, M&A, or director dealing, nor is it a summary factsheet or presentation. This fits the fallback category for miscellaneous regulatory filings.
2026-04-01 English
Environmental, Social and Governance Report 2025
Regulatory Filings
2026-03-31 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.